ClinicalTrials.gg
CompletedNCT01427751Updated Apr 18, 2019Results posted

Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion

A Phase 4 interventional study of dexamethasone intravitreal implant and ranibizumab in Retinal Vein Occlusion and Macular Edema, sponsored by Allergan. Completed at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.

Enrollment
6th of 47
307 · median 56
Started
2011
with 4 others
Phase 4
13 of 47
none open now
Registered
20th of 47
by date
Lead sponsor
1 of 47
Allergan

Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 6th largest by enrollment, is one of 5 that started in 2011, is one of 13 in phase 4, and was the 20th registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 47 studies testing ranibizumab in Retinal Vein Occlusion as a file.
02

Study summary

This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).

03

Conditions studied

  • Retinal Vein Occlusion
  • Macular Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of branch retinal vein occlusion in at least one eye
  • Visual acuity between 20/400 to 20/40

Exclusion criteria

Exclusion Criteria:

  • Active eye infection
  • Ocular hypertension which is not controlled on monotherapy (one medication)
  • Anticipated need for eye surgery during the study
  • Cataract surgery in either eye within 3 months
  • Eye surgery including laser of any type within 6 months
  • Anti-VEGF treatment in either eye (eg, Lucentis®) within 3 months or systemic anti-VEGF treatment (eg, Avastin) within 6 months
  • Use of ocular within 3 months
  • Use of steroids (except for inhaled or intranasal) within 1 month or anticipated use during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Active comparator
    Ozurdex®

    Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.

    Drug: dexamethasone intravitreal implant

  • Active comparator
    Lucentis®

    Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.

    Biological: ranibizumab

Interventions

  • Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.

    Also known as: Ozurdex®

  • Biologicalranibizumab

    Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.

    Also known as: Lucentis®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA)

    BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity) A positive change from Baseline (more letters read correctly) indicates improvement.

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Change From Baseline in Central Retinal Subfield Thickness Using Optical Coherence Tomography (OCT)

    Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye after pupil dilation at Baseline and Month 12. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 12

  2. Percentage of Patients With 15-or-More Letter Improvement in BCVA

    BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity). An improvement in the number of letters read means that the vision has improved.

    Time frame: Baseline, Month 12

  3. Percentage of Patients With a 15-or-More Letter Decrease in BCVA

    BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).

    Time frame: Baseline, Month 12

  4. Time to BCVA Improvement of 15-or-More Letters

    BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The time in days to BCVA improvement of 15-or-More letters.

    Time frame: 12 Months

  5. Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25)

    The VFQ-25 includes 25 vision-targeted questions plus one general health question which assess visual impairment on functioning and specific aspects of health-related quality of life for a total possible composite score of 0 (worst) to 100 (best functionality). A positive change from Baseline indicates improvement.

    Time frame: Baseline, Month 12

  6. Percentage of Participants Not Completing the Month 12 Visit Due to Treatment Failure

    Treatment failure was defined as withdrawal of the participant from treatment or from the study by the investigator before the final visit because of a lack of efficacy.

    Time frame: 12 Months

07

Results

Posted Feb 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneOzurdex®Lucentis®
Started154153
Completed112139
Not completed4214
Withdrew: Adverse event182
Withdrew: No further treatment benefit expected51
Withdrew: Lost to follow-up31
Withdrew: Withdrawal of consent22
Withdrew: Protocol violation64
Withdrew: Death20
Withdrew: Other miscellaneous reasons64

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA)

BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity) A positive change from Baseline (more letters read correctly) indicates improvement.

Time frame:
Baseline, Month 12
Reported as:
Mean · letters
Change From Baseline in Best Corrected Visual Acuity (BCVA)
lettersOzurdex®Lucentis®
Baseline (n=153,153)56.6 ± 10.8959.2 ± 10.92
Change from Baseline at Month 12 (n=153,151)7.9 ± 14.4216.9 ± 12.08
SecondaryChange From Baseline in Central Retinal Subfield Thickness Using Optical Coherence Tomography (OCT)

Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye after pupil dilation at Baseline and Month 12. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 12
Reported as:
Mean · microns
Change From Baseline in Central Retinal Subfield Thickness Using Optical Coherence Tomography (OCT)
micronsOzurdex®Lucentis®
Baseline (n=149, 149)553.2 ± 170.15561.0 ± 188.93
Change from Baseline at Month 12 (n=140,144)-219.2 ± 180.51-253.5 ± 197.08
SecondaryPercentage of Patients With 15-or-More Letter Improvement in BCVA

BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity). An improvement in the number of letters read means that the vision has improved.

Time frame:
Baseline, Month 12
Reported as:
Number · percentage of participants
Percentage of Patients With 15-or-More Letter Improvement in BCVA
percentage of participantsOzurdex®Lucentis®
Percentage of Patients With 15-or-More Letter Improvement in BCVA33.859.5
SecondaryPercentage of Patients With a 15-or-More Letter Decrease in BCVA

BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).

Time frame:
Baseline, Month 12
Reported as:
Number · percentage of participants
Percentage of Patients With a 15-or-More Letter Decrease in BCVA
percentage of participantsOzurdex®Lucentis®
Percentage of Patients With a 15-or-More Letter Decrease in BCVA9.10.7
SecondaryTime to BCVA Improvement of 15-or-More Letters

BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The time in days to BCVA improvement of 15-or-More letters.

Time frame:
12 Months
Reported as:
Mean · days
Time to BCVA Improvement of 15-or-More Letters
daysOzurdex®Lucentis®
Time to BCVA Improvement of 15-or-More Letters73.7 ± 79.6882.0 ± 93.78
SecondaryChange From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25)

The VFQ-25 includes 25 vision-targeted questions plus one general health question which assess visual impairment on functioning and specific aspects of health-related quality of life for a total possible composite score of 0 (worst) to 100 (best functionality). A positive change from Baseline indicates improvement.

Time frame:
Baseline, Month 12
Reported as:
Mean · score on a scale
Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25)
score on a scaleOzurdex®Lucentis®
Baseline (n=143,139)78.1 ± 16.5880.7 ± 14.34
Change from Baseline at Month 12 (n=143, 139)3.5 ± 12.216.6 ± 13.45
SecondaryPercentage of Participants Not Completing the Month 12 Visit Due to Treatment Failure

Treatment failure was defined as withdrawal of the participant from treatment or from the study by the investigator before the final visit because of a lack of efficacy.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants Not Completing the Month 12 Visit Due to Treatment Failure
percentage of participantsOzurdex®Lucentis®
Percentage of Participants Not Completing the Month 12 Visit Due to Treatment Failure4.50.7

Adverse events

Collected over Up to 60 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ozurdex®—12/153 (7.8%)127/153 (83%)
Lucentis®—16/150 (10.7%)104/150 (69.3%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventOzurdex®Lucentis®
Angina pectorisCardiac disorders0/1531/150
Myocardial infarctionCardiac disorders0/1531/150
Myocardial ischaemiaCardiac disorders0/1531/150
PalpitationsCardiac disorders0/1531/150
Subarachnoid haemorrhageNervous system disorders0/1531/150
AnxietyPsychiatric disorders0/1531/150
Catheter site related reactionGeneral disorders0/1531/150
Diverticulum intestinalGastrointestinal disorders0/1531/150
Gastric ulcerGastrointestinal disorders0/1531/150
HaematemesisGastrointestinal disorders0/1531/150
Most frequent other events
Showing 10 of 15
Most frequent other events
EventOzurdex®Lucentis®
Intraocular pressure increasedInvestigations50/15316/150
Conjunctival haemorrhageEye disorders28/15317/150
Macular oedemaEye disorders20/1534/150
Visual acuity reducedEye disorders18/1533/150
CataractEye disorders13/1532/150
HypertensionVascular disorders5/15310/150
Lenticular opacitiesEye disorders10/1530/150
Vitreous floatersEye disorders9/1539/150
Eye painEye disorders6/1539/150
ConjunctivitisEye disorders6/1539/150

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ozurdex®Lucentis®Total
Mean68.4 ± 10.5865.5 ± 12.0467.0 ± 11.41
Sex: Female, Male
Sex: Female, Male(Participants)Ozurdex®Lucentis®Total
Female6266128
Male9287179
08

Study locations

6 sites
  • Paris, France
  • Munich, Germany
  • Tel Aviv, Israel
  • Milan, Italy
  • Madrid, Spain
  • London, United Kingdom
09

References and documents

Publications

  • Bandello F, Augustin A, Tufail A, Leaback R. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol. 2018 Nov;28(6):697-705. doi: 10.1177/1120672117750058. Epub 2018 Apr 9. PubMed 29631435 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Nov 2014, 36 months.

Results were first posted in Feb 2016, 1 year 3 months after primary completion.

Of 19 phase 4 interventional studies under Retinal Vein Occlusion, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2011
First posted
Sep 2, 2011
StartActual
Oct 11, 2011
Primary completionActual
Nov 4, 2014
CompletionActual
Nov 4, 2014
Results first posted
Feb 15, 2016
Last update
Apr 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01427751
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Sep 2, 2011
Start date
Oct 11, 2011
Primary completion
Nov 4, 2014
Completion
Nov 4, 2014
Results posted
Feb 15, 2016
Last update
Apr 18, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone Intravitreal Implant · Ranibizumab

Start the discussion